Back to top
more

Aileron Therapeutics (ALRN)

(Delayed Data from NSDQ)

$5.00 USD

5.00
80,550

+0.07 (1.42%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $5.00 0.00 (0.00%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ALRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aileron Therapeutics, Inc. [ALRN]

Reports for Purchase

Showing records 1 - 20 ( 42 total )

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/10/2023

Company Report

Pages: 6

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/21/2023

Daily Note

Pages: 3

Aileron Terminates Phase 1b Breast Cancer Chemoprotection Study; Exploring Strategic Alternatives

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/02/2022

Company Report

Pages: 7

3Q22 Results; Initial Phase 1b Breast Cancer Data Could be Announced This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

10/26/2022

Daily Note

Pages: 3

New Findings From Phase 1 Study of ALRN-6924 in Healthy Volunteers Presented at EORTC-NCI-AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/16/2022

Company Report

Pages: 6

2Q22 Results; Phase 1b Breast Cancer Study to Reinstate Enrollment in the Coming Weeks

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/01/2022

Company Report

Pages: 7

Downgrade to Neutral Following Challenges and Changes For ALRN-6924 Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

06/30/2022

Company Report

Pages: 8

Disappointing Data for ALRN-6924; Exiting NSCLC Space; Cutting Price Target in Half

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/20/2022

Company Report

Pages: 8

KOL Investor Event Highlights; Three Important Data Readouts Remaining in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/09/2022

Company Report

Pages: 8

1Q22 Results; Interim Phase 1b ALRN-6924 Data in NSCLC Patients Expected Next Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/29/2022

Company Report

Pages: 8

4Q21 Results; Interim ALRN-6924 Data Expected Next Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/05/2022

Daily Note

Pages: 3

Business Update; New Phase 1b Study of ALRN-6924 in Neoadjuvant Breast Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/12/2021

Company Report

Pages: 8

3Q21 Results; NSCLC Phase 1b Study Data Timing Slightly Delayed Due to the COVID Pandemic

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ALRN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

09/16/2021

Daily Note

Pages: 3

ALRN-6924 Healthy Volunteer Data and Final SCLC Results at ESMO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/27/2021

Daily Note

Pages: 3

Initial Findings From Healthy Volunteer Study With ALRN-6924

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/12/2021

Company Report

Pages: 8

2Q21 Results; ALRN-6924 in NSCLC Interim Safety Data Expected by YE21, Top-line Results in Mid-2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

07/01/2021

Daily Note

Pages: 3

ALRN-6924 Trial in Advanced Non-Small Cell Lung Cancer Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/12/2021

Company Report

Pages: 8

1Q21 Results; ALRN-6924 Phase 1b Trial Expected to Initiate This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/25/2021

Company Report

Pages: 8

4Q20 Results; Interim Phase 1b Data for ALRN-6924 Expected by YE21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Aileron Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

01/11/2021

Company Report

Pages: 7

Business Update; Direct Offering and ATM Remove Financial Overhang

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party